Cartesian Therapeutics, Inc. Common Stock (RNAC) is a publicly traded Healthcare sector company. As of May 21, 2026, RNAC trades at $6.65 with a market cap of $202.44M and a P/E ratio of -1.27. RNAC moved +7.31% today. Year to date, RNAC is -5.64%; over the trailing twelve months it is -36.27%. Its 52-week range spans $5.60 to $26.50. Analyst consensus is strong buy with an average price target of $32.20. Rallies surfaces RNAC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cartesian Therapeutics, Inc. Common Stock (RNAC) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. RNAC moved +7.31% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $6.65 |
| Market Cap | $202.44M |
| P/E Ratio | -1.27 |
| EPS | $-5.02 |
| Dividend Yield | 0.00% |
| 52-Week High | $26.50 |
| 52-Week Low | $5.60 |
| Volume | 300 |
| Avg Volume | 0 |
| Revenue (TTM) | $2.80M |
| Net Income | $-130.30M |
| Gross Margin | 0.00% |
6 analysts cover RNAC: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.20.